Machine Learning

Kentro promotes JT Robinson to CTO, cementing its 'AI-first' strategy to transform federal agencies with advanced data platforms and mission-driven tech.

A new pilot program uses AI to find hidden patterns in past cancer trial data, aiming to get the right drugs to the right patients, faster.

With strong revenue, key AI upgrades, and a top Microsoft award, Blue Yonder is solidifying its market lead as global supply chain pressures intensify.

Waters finalized its $18.8B merger with BD's units, doubling its size. But investor concerns over near-term performance sent shares tumbling.

As energy markets face unprecedented volatility, a new platform promises radical transparency, challenging the opaque risk systems traders have long relied on.

A new 'zero-disruption' plate from TheWell Bioscience aims to solve key challenges in organoid research, promising more reliable data for drug discovery.

A new PropTech startup is using a memorable phone number and advanced AI to bypass Zillow, promising cheaper, more accurate home valuations for everyone.

Bionano's 2026 virtual event will showcase how Optical Genome Mapping is revolutionizing cancer and genetic disease research and paving a path to clinical use.

Backed by a proven billion-dollar impact model, 14 new startups are using AI, neuroscience, and philanthropy to revolutionize mental healthcare.

A landmark deal will see Takeda use Iambic's AI platform to slash drug development timelines and fast-track new medicines for cancer and other diseases.

With five conferences in its sights, Voyager Therapeutics is making a major push to win over investors ahead of a pivotal year for its neurological pipeline.

With a promising spinal cord injury drug nearing late-stage trials, NervGen appoints interim leader Dr. Adam Rogers as permanent CEO to guide the breakthrough.

Bruker divisions unveil an open, AI-driven platform at SLAS2026, aiming to unify fragmented labs and enable 24/7 autonomous scientific discovery.

The race to power AI is on. Fermi America's massive private grid in Texas shows how new energy infrastructure is being built to bypass public grid limits.

The Middle East healthcare giant posts record profits and a $163M dividend, fueled by aggressive international acquisitions and a major bet on AI technology.

With a new CEO from Visa-acquired Featurespace and fresh private equity backing, Ripjar is escalating its AI-driven battle against global financial crime.

A new German partnership aims to create variant-ready, room-temperature stable vaccines, moving beyond the limits of first-generation mRNA technology.

Global giant CSL taps Swiss biotech Memo Therapeutics in a landmark deal, signaling a major shift from plasma to lab-grown immunotherapies.

Median Technologies' eyonis® LCS gains landmark FDA clearance, promising to revolutionize early detection of the deadliest cancer with its AI-powered diagnostics.

Johnson & Johnson unveils promising data for its next-gen AFib tech while reinforcing the safety of its current platform in a competitive market.